kw 2189 has been researched along with Carcinoma, Small Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funayama, Y; Isogai, Y; Kanzawa, F; Kuraishi, Y; Lee, YS; Nishio, K; Ogasawara, H; Ohira, T; Saijo, N | 1 |
| Funayama, Y; Isogai, Y; Kubota, N; Kuraishi, Y; Nishio, K; Ogasawara, H; Ohira, T; Ohmori, T; Saijo, N; Takeda, Y | 1 |
2 other study(ies) available for kw 2189 and Carcinoma, Small Cell
| Article | Year |
|---|---|
Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA; Drug Resistance; Drug Resistance, Multiple; Duocarmycins; Female; Humans; Irinotecan; Lung Neoplasms; Microsomes; Ovarian Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 1995 |
A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells.
Topics: Antibiotics, Antineoplastic; Carboxylic Ester Hydrolases; Carcinoma, Small Cell; Cell Survival; DNA Damage; DNA, Neoplasm; Duocarmycins; Humans; In Vitro Techniques; Lung Neoplasms; Pyrrolidinones; Restriction Mapping; Tumor Cells, Cultured | 1994 |